• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ultragenyx Pharmaceu (NQ: RARE )

    42.25 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 9, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 42.25
    Bid (Size) 40.31 (1)
    Ask (Size) 44.00 (3)
    Prev. Close 42.25
    Today's Range 42.25 - 42.25
    52wk Range 31.52 - 54.56
    Shares Outstanding 70,814,462
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
    With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
    Via InvestorPlace

    Performance

    YTD
    -12.29%
    -12.29%
    1 Month
    +0.67%
    +0.67%
    3 Month
    -16.44%
    -16.44%
    6 Month
    -12.62%
    -12.62%
    1 Year
    -4.30%
    -4.30%

    More News

    Read More
    Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Peeling Back The Layers: Exploring Ultragenyx Pharmaceutical Through Analyst Insights
    Via Benzinga
    Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical
    Via Benzinga
    Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Dave & Buster's Posts Downbeat Results, Joins J.Jill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    Via Benzinga
    Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    This United Airlines Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
    Via Benzinga
    Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Legal
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    RARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Crude Oil Down 1%; Charles Schwab Sales Top Estimates
    Via Benzinga
    Topics Stocks
    Exposures Fossil Fuels US Equities
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.